In contrast, selectively targeting IL‐6 trans‐signaling, for example, with agents modeled on soluble glycoprotein 130 Fc fusion protein signal transducer and activator of transcription (sgp130Fc), could inhibit the deleterious, inflammation‐amplifying arm while preserving host defense mediated by the classic signaling pathway, a precision strategy that may improve therapeutic efficacy against inflammatory diseases and represents a promising treatment for complex conditions such as sepsis [115]. The gene discussed is IL6; the disease is Sepsis.